The TOT-HER3 trial is still enrolling patients to evaluate the biological activity of HER3-DXd, measured as the CelTIL score increased post-treatment (C1D21) in patients with HR+/HER2-negative breast cancer and patients with TNBC tumors. Here, ERBB2 is linked to breast cancer.